Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

Study Overview
=================
Brief Summary
-----------------
A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.

Detailed Description
-----------------
Brain-derived neurotrophic factor (BDNF) is considered a biomarker of brain plasticity. Since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.

Official Title
-----------------
Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Genetic: BDNF analysis (Elisa KIT)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle not having received physiotherapy treatment for this same process in the last 3 months. ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent. Exclusion Criteria: Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic Pain Patient<br>A blood draw is to be performed to analyze peripheral BDNF. | Genetic: BDNF analysis (Elisa KIT)<br>* Analysis of peripheral BDNF will be performed<br>|
| Asymptomatic subject<br>A blood draw is to be performed to analyze peripheral BDNF. | Genetic: BDNF analysis (Elisa KIT)<br>* Analysis of peripheral BDNF will be performed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BDNF Levels | Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer [1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker. | 3 hours | 
| Pain Intensity | Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being no pain and the other extreme being the worst pain imaginable | 3 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BDNF